PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1401859
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1401859
Pharmacogenomics Market Forecasts to 2030 - Global Analysis By Distribution Channel, Technology, Application, End User and By Geography
According to Stratistics MRC, the Global Pharmacogenomics Market is accounted for $16.66 billion in 2023 and is expected to reach $34.81 billion by 2030 growing at a CAGR of 11.1% during the forecast period. The study of developing drugs by analysing genetic variations in humans that affect an individual's response to a particular drug is known as pharmacogenomics. This approach is vital for precision medicine, offering personalised treatment plans based on genetic markers. It is essential to improving patient outcomes, reducing adverse drug reactions, enhancing medication efficacy, and providing more cost-effective healthcare.
According to data published by National Cancer Institute in September 2020, stated that an estimated 1,806,590 new cases of cancer will be diagnosed in the U.S. and 606,520 people will die from the disease in 2020.
Market Dynamics:
Driver:
Increasing adoption of personalized medicine
Personalised medicine is an approach that tailors medical treatments to an individual's genetic, genomic, and clinical characteristics. It aims to maximise treatment effectiveness, minimise side effects, and improve patient outcomes by customising healthcare interventions. As patients and healthcare providers become more aware of the potential benefits of pharmacogenomics, the demand for genetic testing and personalised treatment plans is on the rise. Furthermore, pharmaceutical companies are also investing in targeted therapies based on genomic data. This convergence of patient demand, clinical relevance, and industry innovation is propelling the growth of the pharmacogenomics market.
Restraint:
Cost barriers
Cost barriers pose a significant restraint on the Pharmacogenomics market. Genetic testing and pharmacogenomic services can be expensive, making them inaccessible to many patients and healthcare systems. The high costs of DNA sequencing, data analysis, and interpretation can limit the adoption of pharmacogenomics, especially in resource-constrained environments. This financial burden can result in unequal access to the benefits of personalised medicine, exacerbating healthcare disparities.
Opportunity:
Advancements in genetic testing technologies
Developments in genetic testing can spur growth by lowering the cost, increasing accessibility, and expanding the availability of testing. Genetic testing is getting easier to obtain, less expensive, and more accurate as technology advances. Furthermore, the process is made easier for patients and healthcare professionals by the creation of user-friendly at-home testing kits and mobile health applications. Moreover, these developments not only simplify genetic information availability for individuals but also make it easier to incorporate pharmacogenomic data into standard therapeutic procedures. Growing pharmacogenomics market share and wider adoption of personalised medicine are made possible by the increasing prevalence of genetic testing.
Threat:
Data privacy and security
Genetic information is highly sensitive, and the mishandling or unauthorised access to this data could lead to privacy breaches, identity theft, or discrimination. Patients may be hesitant to undergo genetic testing or share their data, fearing potential misuse. Furthermore, regulatory frameworks for safeguarding genetic information are continually evolving and can create compliance challenges for healthcare providers and pharmaceutical companies. Hence, it will lead to a decrease in market growth.
COVID-19 Impact
The COVID-19 pandemic has had a multifaceted impact on the market. On one hand, it accelerated the adoption of digital health, including telehealth and remote monitoring, which can complement pharmacogenomics by facilitating data sharing and patient consultations. The urgency of the pandemic also led to increased research and investment in healthcare and pharmaceuticals, potentially driving advancements in pharmacogenomics. However, there were negative effects as well. Many healthcare resources and research efforts were redirected toward COVID-19, potentially slowing the progress of pharmacogenomics projects. Clinical trials for pharmacogenomic therapies may have been delayed or disrupted due to lockdowns and safety concerns.
The DNA Sequencing segment is expected to be the largest during the forecast period
The DNA Sequencing segment is estimated to hold the largest share. DNA sequencing involves determining the precise order of DNA bases in an individual's genome. By analysing genetic variations, researchers and healthcare providers can identify specific genes and genetic markers relevant to drug response and disease susceptibility. This information enables the customization of medical treatments, ensuring the most effective and safe therapeutic options for patients. In addition, advances in DNA sequencing technologies, such as next-generation sequencing, have made it faster and more cost-effective to obtain genomic data, driving the growth of this segment and expanding the potential applications of pharmacogenomics in healthcare.
The Hospitals & Clinics segment is expected to have the highest CAGR during the forecast period
The Hospitals & Clinics segment is anticipated to have lucrative growth during the forecast period. The healthcare facilities utilise pharmacogenomic testing to customise drug treatment plans, ensuring that medications are both effective and safe for individual patients. Pharmacogenomics can help clinicians identify the most suitable drug therapies and dosages, minimising adverse reactions and optimising patient outcomes. Furthermore, it aids in the selection of treatments for various medical conditions, from cancer to cardiovascular diseases. As the demand for personalised medicine grows, hospitals and clinics are essential in integrating pharmacogenomics into routine clinical practice, revolutionising healthcare by providing individualised, data-driven treatment plans.
Region with largest share:
Asia Pacific commanded the largest market share during the extrapolated period. The Asia-Pacific region is a significant and rapidly growing market for pharmacogenomics. The region faces a rising burden of chronic diseases, including cancer, cardiovascular diseases, and diabetes, which has led to a growing demand for personalised medicine and pharmacogenomic solutions. Countries in the Asia-Pacific region, such as China, Japan, and South Korea, have made substantial investments in genomics research, leading to significant advancements in understanding genetic factors influencing drug responses and diseases.
Region with highest CAGR:
North America is expected to witness profitable growth over the projection period. North America boasts advanced healthcare systems, including well-established hospitals, research institutions, and pharmaceutical companies, providing a solid foundation for the growth of pharmacogenomics. Regulatory agencies, such as the FDA in the United States, have been proactive in recognising the importance of pharmacogenomics in drug development, approval, and labelling, which accelerates its adoption. Furthermore, North American pharmaceutical companies have heavily invested in pharmacogenomics, resulting in the development of numerous personalised therapies. The region is at the forefront of pharmacogenomic research, with substantial investments in genomic studies, clinical trials, and the development of targeted therapies.
Key players in the market:
Some of the key players in the Pharmacogenomics Market include Novartis AG, Ferndale Pharma Group, Inc., Mylan N.V., F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Pfizer Inc., AstraZeneca, Merck & Co., Inc., Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., Lupin, NATCO Pharma Limited, Teva Pharmaceutical Industries Ltd, AbbVie Inc., Boehringer Ingelheim International GmbH, Abbott, Bayer AG, Thermo Fisher Scientific, Inc., Admera Health and Agilent Technologies.
Key Developments:
In October 2023, Novartis, a global leader in immuno-dermatology and rheumatology, announced that the US Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) to treat moderate to severe hidradenitis suppurativa (HS) in adults. Cosentyx is the only FDA-approved fully human biologic that directly inhibits interleukin-17A (IL-17A), a cytokine believed to be involved in the inflammation of HS.2
In October 2023, Pfizer Inc. and BioNTech SE announced positive topline results from a Phase 1/2 study evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age.
In October 2023, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved PENBRAYA (meningococcal groups A, B, C, W and Y vaccine), the first and only pentavalent vaccine that provides coverage against the most common serogroups causing meningococcal disease in adolescents and young adults 10 through 25 years of age.
Distribution Channels Covered:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Technologies Covered:
- DNA Sequencing
- Polymerase Chain Reaction
- Microarray
- Mass Spectrometry
- Electrophoresis
Applications Covered:
- Drug Discovery
- Oncology
- Neurology
- Pain Management
- Cardiovascular diseases
- Psychiatry
- Infectious diseases
- Other Applications
End Users Covered:
- Hospitals & Clinics
- Research Institutions and Academic Institutes
- Other End Users
Regions Covered:
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
- South America
- Argentina
- Brazil
- Chile
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
- Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
- Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
- Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
- 2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions
3 Market Trend Analysis
- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Technology Analysis
- 3.7 Application Analysis
- 3.8 End User Analysis
- 3.9 Emerging Markets
- 3.10 Impact of Covid-19
4 Porters Five Force Analysis
- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry
5 Global Pharmacogenomics Market, By Distribution Channel
- 5.1 Introduction
- 5.2 Hospital Pharmacy
- 5.3 Retail Pharmacy
- 5.4 Online Pharmacy
6 Global Pharmacogenomics Market, By Technology
- 6.1 Introduction
- 6.2 DNA Sequencing
- 6.3 Polymerase Chain Reaction
- 6.4 Microarray
- 6.5 Mass Spectrometry
- 6.6 Electrophoresis
7 Global Pharmacogenomics Market, By Application
- 7.1 Introduction
- 7.2 Drug Discovery
- 7.3 Oncology
- 7.4 Neurology
- 7.5 Pain Management
- 7.6 Cardiovascular diseases
- 7.7 Psychiatry
- 7.8 Infectious diseases
- 7.9 Other Applications
8 Global Pharmacogenomics Market, By End User
- 8.1 Introduction
- 8.2 Hospitals & Clinics
- 8.3 Research Institutions and Academic Institutes
- 8.4 Other End Users
9 Global Pharmacogenomics Market, By Geography
- 9.1 Introduction
- 9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
- 9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
- 9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa
10 Key Developments
- 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 10.2 Acquisitions & Mergers
- 10.3 New Product Launch
- 10.4 Expansions
- 10.5 Other Key Strategies
11 Company Profiling
- 11.1 Novartis AG
- 11.2 Ferndale Pharma Group, Inc.
- 11.3 Mylan N.V.
- 11.4 F. Hoffmann-La Roche Ltd
- 11.5 Takeda Pharmaceutical Company Limited
- 11.6 Pfizer Inc.
- 11.7 AstraZeneca
- 11.8 Merck & Co., Inc.
- 11.9 Eli Lilly and Company
- 11.10 Sun Pharmaceutical Industries Ltd.
- 11.11 Lupin
- 11.12 NATCO Pharma Limited
- 11.13 Teva Pharmaceutical Industries Ltd
- 11.14 AbbVie Inc.
- 11.15 Boehringer Ingelheim International GmbH
- 11.16 Abbott
- 11.17 Bayer AG
- 11.18 Thermo Fisher Scientific, Inc.
- 11.19 Admera Health
- 11.20 Agilent Technologies
List of Tables
- Table 1 Global Pharmacogenomics Market Outlook, By Region (2021-2030) ($MN)
- Table 2 Global Pharmacogenomics Market Outlook, By Distribution Channel (2021-2030) ($MN)
- Table 3 Global Pharmacogenomics Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
- Table 4 Global Pharmacogenomics Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
- Table 5 Global Pharmacogenomics Market Outlook, By Online Pharmacy (2021-2030) ($MN)
- Table 6 Global Pharmacogenomics Market Outlook, By Technology (2021-2030) ($MN)
- Table 7 Global Pharmacogenomics Market Outlook, By DNA Sequencing (2021-2030) ($MN)
- Table 8 Global Pharmacogenomics Market Outlook, By Polymerase Chain Reaction (2021-2030) ($MN)
- Table 9 Global Pharmacogenomics Market Outlook, By Microarray (2021-2030) ($MN)
- Table 10 Global Pharmacogenomics Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
- Table 11 Global Pharmacogenomics Market Outlook, By Electrophoresis (2021-2030) ($MN)
- Table 12 Global Pharmacogenomics Market Outlook, By Application (2021-2030) ($MN)
- Table 13 Global Pharmacogenomics Market Outlook, By Drug Discovery (2021-2030) ($MN)
- Table 14 Global Pharmacogenomics Market Outlook, By Oncology (2021-2030) ($MN)
- Table 15 Global Pharmacogenomics Market Outlook, By Neurology (2021-2030) ($MN)
- Table 16 Global Pharmacogenomics Market Outlook, By Pain Management (2021-2030) ($MN)
- Table 17 Global Pharmacogenomics Market Outlook, By Cardiovascular diseases (2021-2030) ($MN)
- Table 18 Global Pharmacogenomics Market Outlook, By Psychiatry (2021-2030) ($MN)
- Table 19 Global Pharmacogenomics Market Outlook, By Infectious diseases (2021-2030) ($MN)
- Table 20 Global Pharmacogenomics Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 21 Global Pharmacogenomics Market Outlook, By End User (2021-2030) ($MN)
- Table 22 Global Pharmacogenomics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
- Table 23 Global Pharmacogenomics Market Outlook, By Research Institutions and Academic Institutes (2021-2030) ($MN)
- Table 24 Global Pharmacogenomics Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 25 North America Pharmacogenomics Market Outlook, By Country (2021-2030) ($MN)
- Table 26 North America Pharmacogenomics Market Outlook, By Distribution Channel (2021-2030) ($MN)
- Table 27 North America Pharmacogenomics Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
- Table 28 North America Pharmacogenomics Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
- Table 29 North America Pharmacogenomics Market Outlook, By Online Pharmacy (2021-2030) ($MN)
- Table 30 North America Pharmacogenomics Market Outlook, By Technology (2021-2030) ($MN)
- Table 31 North America Pharmacogenomics Market Outlook, By DNA Sequencing (2021-2030) ($MN)
- Table 32 North America Pharmacogenomics Market Outlook, By Polymerase Chain Reaction (2021-2030) ($MN)
- Table 33 North America Pharmacogenomics Market Outlook, By Microarray (2021-2030) ($MN)
- Table 34 North America Pharmacogenomics Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
- Table 35 North America Pharmacogenomics Market Outlook, By Electrophoresis (2021-2030) ($MN)
- Table 36 North America Pharmacogenomics Market Outlook, By Application (2021-2030) ($MN)
- Table 37 North America Pharmacogenomics Market Outlook, By Drug Discovery (2021-2030) ($MN)
- Table 38 North America Pharmacogenomics Market Outlook, By Oncology (2021-2030) ($MN)
- Table 39 North America Pharmacogenomics Market Outlook, By Neurology (2021-2030) ($MN)
- Table 40 North America Pharmacogenomics Market Outlook, By Pain Management (2021-2030) ($MN)
- Table 41 North America Pharmacogenomics Market Outlook, By Cardiovascular diseases (2021-2030) ($MN)
- Table 42 North America Pharmacogenomics Market Outlook, By Psychiatry (2021-2030) ($MN)
- Table 43 North America Pharmacogenomics Market Outlook, By Infectious diseases (2021-2030) ($MN)
- Table 44 North America Pharmacogenomics Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 45 North America Pharmacogenomics Market Outlook, By End User (2021-2030) ($MN)
- Table 46 North America Pharmacogenomics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
- Table 47 North America Pharmacogenomics Market Outlook, By Research Institutions and Academic Institutes (2021-2030) ($MN)
- Table 48 North America Pharmacogenomics Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 49 Europe Pharmacogenomics Market Outlook, By Country (2021-2030) ($MN)
- Table 50 Europe Pharmacogenomics Market Outlook, By Distribution Channel (2021-2030) ($MN)
- Table 51 Europe Pharmacogenomics Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
- Table 52 Europe Pharmacogenomics Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
- Table 53 Europe Pharmacogenomics Market Outlook, By Online Pharmacy (2021-2030) ($MN)
- Table 54 Europe Pharmacogenomics Market Outlook, By Technology (2021-2030) ($MN)
- Table 55 Europe Pharmacogenomics Market Outlook, By DNA Sequencing (2021-2030) ($MN)
- Table 56 Europe Pharmacogenomics Market Outlook, By Polymerase Chain Reaction (2021-2030) ($MN)
- Table 57 Europe Pharmacogenomics Market Outlook, By Microarray (2021-2030) ($MN)
- Table 58 Europe Pharmacogenomics Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
- Table 59 Europe Pharmacogenomics Market Outlook, By Electrophoresis (2021-2030) ($MN)
- Table 60 Europe Pharmacogenomics Market Outlook, By Application (2021-2030) ($MN)
- Table 61 Europe Pharmacogenomics Market Outlook, By Drug Discovery (2021-2030) ($MN)
- Table 62 Europe Pharmacogenomics Market Outlook, By Oncology (2021-2030) ($MN)
- Table 63 Europe Pharmacogenomics Market Outlook, By Neurology (2021-2030) ($MN)
- Table 64 Europe Pharmacogenomics Market Outlook, By Pain Management (2021-2030) ($MN)
- Table 65 Europe Pharmacogenomics Market Outlook, By Cardiovascular diseases (2021-2030) ($MN)
- Table 66 Europe Pharmacogenomics Market Outlook, By Psychiatry (2021-2030) ($MN)
- Table 67 Europe Pharmacogenomics Market Outlook, By Infectious diseases (2021-2030) ($MN)
- Table 68 Europe Pharmacogenomics Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 69 Europe Pharmacogenomics Market Outlook, By End User (2021-2030) ($MN)
- Table 70 Europe Pharmacogenomics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
- Table 71 Europe Pharmacogenomics Market Outlook, By Research Institutions and Academic Institutes (2021-2030) ($MN)
- Table 72 Europe Pharmacogenomics Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 73 Asia Pacific Pharmacogenomics Market Outlook, By Country (2021-2030) ($MN)
- Table 74 Asia Pacific Pharmacogenomics Market Outlook, By Distribution Channel (2021-2030) ($MN)
- Table 75 Asia Pacific Pharmacogenomics Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
- Table 76 Asia Pacific Pharmacogenomics Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
- Table 77 Asia Pacific Pharmacogenomics Market Outlook, By Online Pharmacy (2021-2030) ($MN)
- Table 78 Asia Pacific Pharmacogenomics Market Outlook, By Technology (2021-2030) ($MN)
- Table 79 Asia Pacific Pharmacogenomics Market Outlook, By DNA Sequencing (2021-2030) ($MN)
- Table 80 Asia Pacific Pharmacogenomics Market Outlook, By Polymerase Chain Reaction (2021-2030) ($MN)
- Table 81 Asia Pacific Pharmacogenomics Market Outlook, By Microarray (2021-2030) ($MN)
- Table 82 Asia Pacific Pharmacogenomics Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
- Table 83 Asia Pacific Pharmacogenomics Market Outlook, By Electrophoresis (2021-2030) ($MN)
- Table 84 Asia Pacific Pharmacogenomics Market Outlook, By Application (2021-2030) ($MN)
- Table 85 Asia Pacific Pharmacogenomics Market Outlook, By Drug Discovery (2021-2030) ($MN)
- Table 86 Asia Pacific Pharmacogenomics Market Outlook, By Oncology (2021-2030) ($MN)
- Table 87 Asia Pacific Pharmacogenomics Market Outlook, By Neurology (2021-2030) ($MN)
- Table 88 Asia Pacific Pharmacogenomics Market Outlook, By Pain Management (2021-2030) ($MN)
- Table 89 Asia Pacific Pharmacogenomics Market Outlook, By Cardiovascular diseases (2021-2030) ($MN)
- Table 90 Asia Pacific Pharmacogenomics Market Outlook, By Psychiatry (2021-2030) ($MN)
- Table 91 Asia Pacific Pharmacogenomics Market Outlook, By Infectious diseases (2021-2030) ($MN)
- Table 92 Asia Pacific Pharmacogenomics Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 93 Asia Pacific Pharmacogenomics Market Outlook, By End User (2021-2030) ($MN)
- Table 94 Asia Pacific Pharmacogenomics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
- Table 95 Asia Pacific Pharmacogenomics Market Outlook, By Research Institutions and Academic Institutes (2021-2030) ($MN)
- Table 96 Asia Pacific Pharmacogenomics Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 97 South America Pharmacogenomics Market Outlook, By Country (2021-2030) ($MN)
- Table 98 South America Pharmacogenomics Market Outlook, By Distribution Channel (2021-2030) ($MN)
- Table 99 South America Pharmacogenomics Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
- Table 100 South America Pharmacogenomics Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
- Table 101 South America Pharmacogenomics Market Outlook, By Online Pharmacy (2021-2030) ($MN)
- Table 102 South America Pharmacogenomics Market Outlook, By Technology (2021-2030) ($MN)
- Table 103 South America Pharmacogenomics Market Outlook, By DNA Sequencing (2021-2030) ($MN)
- Table 104 South America Pharmacogenomics Market Outlook, By Polymerase Chain Reaction (2021-2030) ($MN)
- Table 105 South America Pharmacogenomics Market Outlook, By Microarray (2021-2030) ($MN)
- Table 106 South America Pharmacogenomics Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
- Table 107 South America Pharmacogenomics Market Outlook, By Electrophoresis (2021-2030) ($MN)
- Table 108 South America Pharmacogenomics Market Outlook, By Application (2021-2030) ($MN)
- Table 109 South America Pharmacogenomics Market Outlook, By Drug Discovery (2021-2030) ($MN)
- Table 110 South America Pharmacogenomics Market Outlook, By Oncology (2021-2030) ($MN)
- Table 111 South America Pharmacogenomics Market Outlook, By Neurology (2021-2030) ($MN)
- Table 112 South America Pharmacogenomics Market Outlook, By Pain Management (2021-2030) ($MN)
- Table 113 South America Pharmacogenomics Market Outlook, By Cardiovascular diseases (2021-2030) ($MN)
- Table 114 South America Pharmacogenomics Market Outlook, By Psychiatry (2021-2030) ($MN)
- Table 115 South America Pharmacogenomics Market Outlook, By Infectious diseases (2021-2030) ($MN)
- Table 116 South America Pharmacogenomics Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 117 South America Pharmacogenomics Market Outlook, By End User (2021-2030) ($MN)
- Table 118 South America Pharmacogenomics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
- Table 119 South America Pharmacogenomics Market Outlook, By Research Institutions and Academic Institutes (2021-2030) ($MN)
- Table 120 South America Pharmacogenomics Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 121 Middle East & Africa Pharmacogenomics Market Outlook, By Country (2021-2030) ($MN)
- Table 122 Middle East & Africa Pharmacogenomics Market Outlook, By Distribution Channel (2021-2030) ($MN)
- Table 123 Middle East & Africa Pharmacogenomics Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
- Table 124 Middle East & Africa Pharmacogenomics Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
- Table 125 Middle East & Africa Pharmacogenomics Market Outlook, By Online Pharmacy (2021-2030) ($MN)
- Table 126 Middle East & Africa Pharmacogenomics Market Outlook, By Technology (2021-2030) ($MN)
- Table 127 Middle East & Africa Pharmacogenomics Market Outlook, By DNA Sequencing (2021-2030) ($MN)
- Table 128 Middle East & Africa Pharmacogenomics Market Outlook, By Polymerase Chain Reaction (2021-2030) ($MN)
- Table 129 Middle East & Africa Pharmacogenomics Market Outlook, By Microarray (2021-2030) ($MN)
- Table 130 Middle East & Africa Pharmacogenomics Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
- Table 131 Middle East & Africa Pharmacogenomics Market Outlook, By Electrophoresis (2021-2030) ($MN)
- Table 132 Middle East & Africa Pharmacogenomics Market Outlook, By Application (2021-2030) ($MN)
- Table 133 Middle East & Africa Pharmacogenomics Market Outlook, By Drug Discovery (2021-2030) ($MN)
- Table 134 Middle East & Africa Pharmacogenomics Market Outlook, By Oncology (2021-2030) ($MN)
- Table 135 Middle East & Africa Pharmacogenomics Market Outlook, By Neurology (2021-2030) ($MN)
- Table 136 Middle East & Africa Pharmacogenomics Market Outlook, By Pain Management (2021-2030) ($MN)
- Table 137 Middle East & Africa Pharmacogenomics Market Outlook, By Cardiovascular diseases (2021-2030) ($MN)
- Table 138 Middle East & Africa Pharmacogenomics Market Outlook, By Psychiatry (2021-2030) ($MN)
- Table 139 Middle East & Africa Pharmacogenomics Market Outlook, By Infectious diseases (2021-2030) ($MN)
- Table 140 Middle East & Africa Pharmacogenomics Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 141 Middle East & Africa Pharmacogenomics Market Outlook, By End User (2021-2030) ($MN)
- Table 142 Middle East & Africa Pharmacogenomics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
- Table 143 Middle East & Africa Pharmacogenomics Market Outlook, By Research Institutions and Academic Institutes (2021-2030) ($MN)
- Table 144 Middle East & Africa Pharmacogenomics Market Outlook, By Other End Users (2021-2030) ($MN)
